Last reviewed · How we verify

NCT06199128: Fix

Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients

Completed Last updated 10 January 2024
What this trial tests

trial testing carboxymethyl β-glucan in Human Papillomavirus Infection in 533 participants. Completed in 22 November 2023.

Timeline
22 September 2022
Primary endpoint
22 September 2023
22 November 2023

Quick facts

Lead sponsorUriach Consumer Healthcare
StatusCompleted
Study typeOBSERVATIONAL
Enrollment533
Start date22 September 2022
Primary completion22 September 2023
Estimated completion22 November 2023
Sites5 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Uriach Consumer Healthcare

Who can join

Adults 25 to 65, female only, with Human Papillomavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, Controlled, Multicentre, Real Clinical Practice Study. Effectiveness of Carboxymethyl β-Glucan treatment in high-risk HPV+ patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Human Papillomavirus Infection

Currently open trials in the same condition.

Other Uriach Consumer Healthcare trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06199128.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing